Search

Your search keyword '"Pluzanska, A"' showing total 6 results
Start Over Author "Pluzanska, A" Journal european journal of cancer supplements
6 results on '"Pluzanska, A"'

1. 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

Author

C. Chevreau, Alain Ravaud, Bernard Escudier, Sergio Bracarda, Cezary Szczylik, Bohuslav Melichar, P. Koralewski, M. Filipek, Nicola Moore, and A. Pluzanska

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, Patient subgroups, medicine.disease, First line treatment, Renal cell carcinoma, Interferon, Internal medicine, medicine, Progression-free survival, business, medicine.drug
Published
2007
Full Text
View/download PDF

3. 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

Author

Bracarda, S., primary, Koralewski, P., additional, Pluzanska, A., additional, Ravaud, A., additional, Szczylik, C., additional, Chevreau, C., additional, Filipek, M., additional, Melichar, B., additional, Moore, N., additional, and Escudier, B., additional

Published
2007
Full Text
View/download PDF

5. Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) – Post-study chemotherapy (PSC) trend analysis

Author

Anna Pluzanska, Janusz Rolski, Shona Nag, Allen S. Melemed, Lorinda Simms, G. Calderillo-Ruiz, Antonio Llombart, K. Look, J. Gill, and Joyce O'Shaughnessy

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, medicine.disease, Metastatic breast cancer, Gemcitabine, chemistry.chemical_compound, Paclitaxel, chemistry, Internal medicine, Medicine, In patient, business, medicine.drug
Published
2008
Full Text
View/download PDF

6. 4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)

Author

Sergio Bracarda, Cezary Szczylik, Alain Ravaud, P. Koralewski, Bernard Escudier, M. Filipek, Bohuslav Melichar, Nicola Moore, Christine Chevreau, and A. Pluzanska

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, First line, medicine.disease, Renal cell carcinoma, Interferon, Internal medicine, medicine, Progression-free survival, business, medicine.drug
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results